Brief Title: Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab
Status:
Recruiting
Trial end date:
2025-04-26
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the maximum tolerated dose (MTD), recommended Phase
2 dose(RP2D),safety & tolerability of BGB-10188: as monotherapy in participants with mature
B-cell malignancies; oin combination with zanubrutinib in participants with
relapse/refractory follicular lymphoma (R/R FL), mantle cell lymphoma (MCL) or diffuse large
B-cell lymphoma (DLBCL); and in combination with tislelizumab in participants with advanced
solid tumors.